Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent

Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are...

Full description

Saved in:
Bibliographic Details
Published inEcancermedicalscience Vol. 8; p. 443
Main Authors Pantziarka, Pan, Bouche, Gauthier, Meheus, Lydie, Sukhatme, Vidula, Sukhatme, Vikas P
Format Journal Article
LanguageEnglish
Published England Cancer Intelligence 01.01.2014
Subjects
Clinical Study
anti-helminthic
metronomic chemotherapy
cancer
drug repurposing
ReDO Project
Online AccessGet full text
ISSN1754-6605
1754-6605
DOI10.3332/ecancer.2014.443

Cover

More Information
Summary:Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1754-6605
1754-6605
DOI:10.3332/ecancer.2014.443